Aurobindo Pharma is a pharmaceutical company and on 6 February 2025, they have reported Q3 2025 performance of the company.
Aurobindo Pharma reported a mixed financial performance for the December quarter. While the company saw good revenue growth, it experienced a drop in net profit and margins.
Net profit was ₹845.8 crore, a 9.7% decrease compared to ₹936 crore in the same period last year. This was also lower than analysts’ expectations, which had predicted ₹906 crore, indicating a weaker-than-expected performance in terms of profit.
On the positive side, the company’s revenue increased by 8.5% year-on-year (YoY), reaching ₹7,978.5 crore. This was higher than the anticipated ₹7,782.5 crore, with strong sales in important markets like the US and emerging economies helping the growth.
However, the company’s operating performance wasn’t as strong. Earnings before interest, taxes, depreciation, and amortization (EBITDA) decreased by 1.5% YoY to ₹1,627.7 crore, compared to ₹1,601 crore last year. This also missed the forecast of ₹1,636 crore by analysts.
The company’s profit margins also fell, dropping to 20.4% from 21.8% last year, which was below the expected margin of 21%.
Ahead of the earnings announcement, Aurobindo Pharma’s stock ended the trading day flat at ₹1,184.50, down by 0.62%.
1 thought on “Aurobindo Pharma Q3 Results: Revenue Exceeds Expectations, Profit and Margins Strain Under Pressure”